{"title":"Rivastigmine as an Alternative in Physostigmine Shortage for Anticholinergic Toxicity Treatment.","authors":"Omid Mehrpour, Mario Marini, Samaneh Nakhaee","doi":"10.1016/j.yrtph.2025.105857","DOIUrl":null,"url":null,"abstract":"<p><p>Anticholinergic toxicity, a medical emergency characterized by symptoms such as dry mouth, blurred vision, severe delirium, and tachycardia, necessitates prompt and effective intervention. The traditional go-to treatment has been physostigmine, a reversible cholinesterase inhibitor known for its ability to cross the blood-brain barrier (BBB). However, the occasional scarcity of physostigmine has led healthcare professionals to consider alternative treatments, with rivastigmine emerging as a potential candidate (1). This article delves into the feasibility of using rivastigmine as a substitute, focusing on its ability to penetrate the brain and its effectiveness in managing anticholinergic toxicity.</p>","PeriodicalId":20852,"journal":{"name":"Regulatory Toxicology and Pharmacology","volume":" ","pages":"105857"},"PeriodicalIF":3.0000,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Regulatory Toxicology and Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.yrtph.2025.105857","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, LEGAL","Score":null,"Total":0}
引用次数: 0
Abstract
Anticholinergic toxicity, a medical emergency characterized by symptoms such as dry mouth, blurred vision, severe delirium, and tachycardia, necessitates prompt and effective intervention. The traditional go-to treatment has been physostigmine, a reversible cholinesterase inhibitor known for its ability to cross the blood-brain barrier (BBB). However, the occasional scarcity of physostigmine has led healthcare professionals to consider alternative treatments, with rivastigmine emerging as a potential candidate (1). This article delves into the feasibility of using rivastigmine as a substitute, focusing on its ability to penetrate the brain and its effectiveness in managing anticholinergic toxicity.
期刊介绍:
Regulatory Toxicology and Pharmacology publishes peer reviewed articles that involve the generation, evaluation, and interpretation of experimental animal and human data that are of direct importance and relevance for regulatory authorities with respect to toxicological and pharmacological regulations in society. All peer-reviewed articles that are published should be devoted to improve the protection of human health and environment. Reviews and discussions are welcomed that address legal and/or regulatory decisions with respect to risk assessment and management of toxicological and pharmacological compounds on a scientific basis. It addresses an international readership of scientists, risk assessors and managers, and other professionals active in the field of human and environmental health.
Types of peer-reviewed articles published:
-Original research articles of relevance for regulatory aspects covering aspects including, but not limited to:
1.Factors influencing human sensitivity
2.Exposure science related to risk assessment
3.Alternative toxicological test methods
4.Frameworks for evaluation and integration of data in regulatory evaluations
5.Harmonization across regulatory agencies
6.Read-across methods and evaluations
-Contemporary Reviews on policy related Research issues
-Letters to the Editor
-Guest Editorials (by Invitation)